In this episode, Rich is joined by Dr Raghav Sundar and Dr Aishwarya Bandla from the National University Cancer Institute in Singapore. They discuss their research surrounding chemotherapy-induced peripheral neuropathy, which has been paramount in making further steps towards managing this often life-changing side effect.
They discuss why CIPN was often viewed by clinicians as the price to pay for curing cancer when there was no effective intervention on the horizon, and that patients are often unaware of the side effect until they begin to suffer from it. Looking to the future, Raghav and Aish discuss cryocompression as a potential treatment option for CIPN, and why assessment and management protocols surrounding CIPN need to be reviewed.
Oxaliplatin and Paclitaxel cause CIPN, and used to treat breast and colorectal cancer – two of the most common cancer types globally
02:00 – The common drugs causing CIPN and why it is difficult to discuss with the patient as they are not sure what it is until they start treatment
03:40 – Aishwarya’s role with the CIPN project and why she got involved
07:50 – The changes in opinion on the cryocompression device, and the differences in trial uptake 10 years ago versus now
10:20 – What got NUS interested in this research project and why?
13:10 – The development of a device inspired by orthopaedic compression devices, and the effectiveness of cryotherapy for preventing CIA
20:37 – The patient experience of CIPN, and the increasing awareness of it as a side effect. How does numbness impact an individual on a day to day basis? What are the long term impacts?
23:45 – Is there a lack of familiarity with CIPN and clinicians and what causes it? Is that because there are no effective treatment strategies for it?
26:05 – How do you manage a conversation between clinician and patient regarding CIPN?
28:26 – Are there any strategies for CIPN intervention currently?
31:32 – How do we measure and assess CIPN? Discuss the CIPN 20 questionnaire – designed to get a holistic feel of the patient’s numbness
33:20 – How to weigh up QoL and survivorship as a clinician when considering dose reduction when a patient is suffering from CIPN
35:13 – The Paxman and NUS research collaboration- current status and the next steps
38:04 – What would they like to achieve in the future?
39:41 – Requirement for the large randomised study, as previous smaller or one-arm studies on CIPN have not made an impact
40:50 – Will cryocompression for CIPN be accepted in the same way scalp cooling has?
Dr Raghav Sundar, Consultant in the Department of Haematology-Oncology, The National University Cancer Institute in Singapore
Dr Aishwarya Bandla, Senior Research Fellow, The National University Cancer Institute in Singapore
Weekly paclitaxel versus standard 3-week schedule in patients with metastatic breast cancer. Halim et al. Journal of Clinical Oncology 29, May 20, 2011. Weekly paclitaxel versus standard 3-week schedule in patients with metastatic breast cancer. | Journal of Clinical Oncology (ascopubs.org)
Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls. Bandla et al., Acta Oncol. Epub 2015 Sep 11. Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls – PubMed (nih.gov)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Loprinzi et al. Journal of Clinical Oncology 2020. ASCO Guideline Update: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers (scalpcoolingstudies.com)
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Jordan et al. July 2020. Systematic anticancer therapy-induced peripheral & central neurotoxicity (scalpcoolingstudies.com
Current Singapore CIPN clinical trial: A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy – Full Text View – ClinicalTrials.gov
In this episode, Rich is joined by Dr Raghav Sundar and Dr Aishwarya Bandla from the National University Cancer Institute in Singapore. They discuss their research surrounding chemotherapy-induced peripheral neuropathy, which has been paramount in making further steps towards managing this often life-changing side effect.
They discuss why CIPN was often viewed by clinicians as the price to pay for curing cancer when there was no effective intervention on the horizon, and that patients are often unaware of the side effect until they begin to suffer from it. Looking to the future, Raghav and Aish discuss cryocompression as a potential treatment option for CIPN, and why assessment and management protocols surrounding CIPN need to be reviewed.
In this episode, Rich is joined by Dr Raghav Sundar and Dr Aishwarya Bandla from the National University Cancer Institute in Singapore. They discuss their research surrounding chemotherapy-induced peripheral neuropathy, which has been paramount in making further steps towards managing this often life-changing side effect.
They discuss why CIPN was often viewed by clinicians as the price to pay for curing cancer when there was no effective intervention on the horizon, and that patients are often unaware of the side effect until they begin to suffer from it. Looking to the future, Raghav and Aish discuss cryocompression as a potential treatment option for CIPN, and why assessment and management protocols surrounding CIPN need to be reviewed.
Oxaliplatin and Paclitaxel cause CIPN, and used to treat breast and colorectal cancer – two of the most common cancer types globally
02:00 – The common drugs causing CIPN and why it is difficult to discuss with the patient as they are not sure what it is until they start treatment
03:40 – Aishwarya’s role with the CIPN project and why she got involved
07:50 – The changes in opinion on the cryocompression device, and the differences in trial uptake 10 years ago versus now
10:20 – What got NUS interested in this research project and why?
13:10 – The development of a device inspired by orthopaedic compression devices, and the effectiveness of cryotherapy for preventing CIA
20:37 – The patient experience of CIPN, and the increasing awareness of it as a side effect. How does numbness impact an individual on a day to day basis? What are the long term impacts?
23:45 – Is there a lack of familiarity with CIPN and clinicians and what causes it? Is that because there are no effective treatment strategies for it?
26:05 – How do you manage a conversation between clinician and patient regarding CIPN?
28:26 – Are there any strategies for CIPN intervention currently?
31:32 – How do we measure and assess CIPN? Discuss the CIPN 20 questionnaire – designed to get a holistic feel of the patient’s numbness
33:20 – How to weigh up QoL and survivorship as a clinician when considering dose reduction when a patient is suffering from CIPN
35:13 – The Paxman and NUS research collaboration- current status and the next steps
38:04 – What would they like to achieve in the future?
39:41 – Requirement for the large randomised study, as previous smaller or one-arm studies on CIPN have not made an impact
40:50 – Will cryocompression for CIPN be accepted in the same way scalp cooling has?
Dr Raghav Sundar, Consultant in the Department of Haematology-Oncology, The National University Cancer Institute in Singapore
Dr Aishwarya Bandla, Senior Research Fellow, The National University Cancer Institute in Singapore
Weekly paclitaxel versus standard 3-week schedule in patients with metastatic breast cancer. Halim et al. Journal of Clinical Oncology 29, May 20, 2011. Weekly paclitaxel versus standard 3-week schedule in patients with metastatic breast cancer. | Journal of Clinical Oncology (ascopubs.org)
Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls. Bandla et al., Acta Oncol. Epub 2015 Sep 11. Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls – PubMed (nih.gov)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Loprinzi et al. Journal of Clinical Oncology 2020. ASCO Guideline Update: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers (scalpcoolingstudies.com)
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Jordan et al. July 2020. Systematic anticancer therapy-induced peripheral & central neurotoxicity (scalpcoolingstudies.com
Current Singapore CIPN clinical trial: A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy – Full Text View – ClinicalTrials.gov
